Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.

Authors
Category Primary study
ConferenceASCO MEETING ABSTRACTS
Year 2025
This article has no abstract
Epistemonikos ID: 3469fab9b52c958960a28804977a77eb2c3b3ede
First added on: Apr 25, 2026